Publication:
CLINICAL-EVALUATION OF LOW-DOSE INTRADERMALLY ADMINISTERED HEPATITIS-B VACCINE - A COMPARISON OF PLASMA-DERIVED AND RECOMBINANT YEAST-DERIVED VACCINES

Simple item page
dc.contributor.authorsSOYLETIR, G; BAHCECI, E; AKOGLU, E; SOYOGUL, U; LAWRANCE, RA
dc.date.accessioned2022-03-13T23:23:06Z
dc.date.available2022-03-13T23:23:06Z
dc.date.issued1992
dc.description.abstractA study of the safety and immunogenicity of plasma-derived and yeast-derived recombinant hepatitis B vaccines administered by the intradermal route is reported. Three groups of medical students were inoculated intradermally at 0, 1 and 6 months with 2-mu-g of vaccine. Group 1 (n = 24) were administered plasma-derived vaccine (Green Cross HB-vaccine), group 2 (n = 21) yeast-derived recombinant vaccine (Engerix B), and group 3 (n = 13) two doses of plasma-derived vaccine with a third dose of yeast-derived vaccine. One month after administration of the third dose of vaccine, seroconversion rates in each of the three groups were 83, 100 and 92%, respectively, with anti-HBs geometric mean titres (GMT) of 329 IU l-1, 1390 IU l-1 and 1061 IU l-1. Although differences in seroconversion rates were not statistically significant, the GMT in group 1 was significantly lower than that in group 2 (p < 0.01) and group 3 (p < 0.05). The results presented show that intradermal administration of plasma-derived or yeast-derived vaccine, or a combination of the two, can provoke an effective immunogenic response to hepatitis B virus at approximately 10% of the cost of intramuscular vaccination. In this study administration of yeast-derived vaccine yielded better results than plasma-derived vaccine when administered by the intradermal route.
dc.identifier.doi10.1016/0264-410X(92)90367-S
dc.identifier.issn0264-410X
dc.identifier.pubmed1533478
dc.identifier.urihttps://hdl.handle.net/11424/238480
dc.identifier.wosWOS:A1992HL42300002
dc.language.isoeng
dc.publisherBUTTERWORTH-HEINEMANN LTD
dc.relation.ispartofVACCINE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHEPATITIS-B
dc.subjectVACCINE
dc.subjectPLASMA-DERIVED
dc.subjectYEAST-DERIVED
dc.subjectINTRADERMAL
dc.subjectVIRUS-VACCINE
dc.subjectIMMUNOGENICITY
dc.subjectADULTS
dc.titleCLINICAL-EVALUATION OF LOW-DOSE INTRADERMALLY ADMINISTERED HEPATITIS-B VACCINE - A COMPARISON OF PLASMA-DERIVED AND RECOMBINANT YEAST-DERIVED VACCINES
dc.typeother
dc.type.subnote
dspace.entity.typePublication
local.avesis.id1c6f2520-6f7e-439a-958a-6a1e49de53e1
local.import.packageSS19
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages4
oaire.citation.endPage304
oaire.citation.issue5
oaire.citation.startPage301
oaire.citation.titleVACCINE
oaire.citation.volume10

Files

Collections

Research Outputs